Immunovant, Inc. financial data

Symbol
IMVT on Nasdaq
Location
320 West 37 Th Street, New York, NY
Fiscal year end
March 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 950 % -26.1%
Debt-to-equity 11.6 % +37.7%
Return On Equity -84.9 % -50.6%
Return On Assets -76.1 % -46.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 175M shares +19.4%
Common Stock, Shares, Outstanding 175M shares +19.1%
Entity Public Float 1.87B USD -14.3%
Common Stock, Value, Issued 17K USD +21.4%
Weighted Average Number of Shares Outstanding, Basic 174M shares +18.6%
Weighted Average Number of Shares Outstanding, Diluted 174M shares +18.6%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 83.5M USD +27.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -462M USD -43.3%
Income Tax Expense (Benefit) 2.24M USD +704%
Net Income (Loss) Attributable to Parent -465M USD -43.9%
Earnings Per Share, Basic -2 USD/shares -28.6%
Earnings Per Share, Diluted -2 USD/shares -28.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 522M USD +10.3%
Accounts Receivable, after Allowance for Credit Loss, Current 1.97M USD +5.01%
Assets, Current 574M USD +13%
Property, Plant and Equipment, Net 632K USD -5.81%
Operating Lease, Right-of-Use Asset 98K USD -26.3%
Other Assets, Noncurrent 8.78M USD +15.3%
Assets 583M USD +13%
Accounts Payable, Current 6.92M USD -66.6%
Accrued Liabilities, Current 50.7M USD +22.9%
Liabilities, Current 63.3M USD -5.1%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 63.3M USD -5.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.45M USD -24.1%
Retained Earnings (Accumulated Deficit) -1.49B USD -45.5%
Stockholders' Equity Attributable to Parent 520M USD +15.7%
Liabilities and Equity 583M USD +13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -117M USD -54.1%
Net Cash Provided by (Used in) Financing Activities 2.92M USD +325%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 175M shares +19.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -115M USD -52.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 522M USD +10.3%
Deferred Tax Assets, Valuation Allowance 219M USD +54.6%
Deferred Tax Assets, Gross 220M USD +55%
Operating Lease, Liability 138K USD -88.7%
Depreciation 107K USD +33.8%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -465M USD -44.3%
Lessee, Operating Lease, Liability, to be Paid 141K USD -88.7%
Operating Lease, Liability, Current 98K USD -29%
Lessee, Operating Lease, Liability, to be Paid, Year Two 47K USD -96.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 141K USD -88.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3K USD -88%
Deferred Tax Assets, Operating Loss Carryforwards 153M USD +56.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Additional Paid in Capital 2B USD +36.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.1M USD +216%
Share-based Payment Arrangement, Expense 54.9M USD +19.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%